Healio
SearchLoading
Healio
SearchLoading

Hawaiian Eye/Retina Meeting
ByI. Paul Singh, MD
ByAnthony DeFino
Fact checked byChristine Klimanskis, ELS

Read more

February 14, 2024
3 min watch
Save

VIDEO: New drug delivery technologies decrease compliance issues in glaucoma

ByI. Paul Singh, MD
ByAnthony DeFino
Fact checked byChristine Klimanskis, ELS

WAILEA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2024, I. Paul Singh, MD, discusses how new opportunities in drug delivery can help limit reliance on patient compliance in glaucoma treatment.

Singh highlights Durysta (bimatoprost intracameral implant, Allergan) and iDose TR (travoprost intracameral implant, Glaukos) as two FDA-approved options for treating glaucoma.

“One of my biggest pearls, now having these opportunities, is to not ignore or minimize the impact of poor compliance,” he said.

Sources/Disclosures

Collapse
Source:

Singh IP. Drug delivery pearls for 2024. Presented at: Hawaiian Eye 2024; Jan. 13-19, 2024; Wailea, Hawaii.

Disclosures: Singh reports being a speaker and consultant for Allergan and Glaukos.

Read more from Hawaiian Eye/Retina Meeting

View all

Read more about

glaucoma
drug delivery system
 

Related Content